AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01032824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Telephone Counseling Intervention
Description: 10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.
Study NCT01032824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group Arm
Description: 10-session didactic telephone group
Study NCT01032824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Book Arm
Description: Book only.
Study NCT02924740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training
Description: Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).
Study NCT02924740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).
Study NCT02924740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaginal Tampon Training
Description: Vaginal tampon training will be applied for 5 days a week for 12 weeks. Exercises with tampons will be performed two days a week by physiotherapist (first author) and three days a week by patients. One set of tampon exercises consist 15 contractions. During vaginal tampon training, from week 1 to week 12, patients were instructed to perform two sets of exercises for five days a week (two days by physiotherapist, three days by themselves).
Study NCT02747511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Study NCT02747511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00110461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
Study NCT00110461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
Study NCT00110461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet
Study NCT00724529 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
Study NCT02929212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Solid Meal
Description: Subjects will receive solid meals during meal study
Study NCT02929212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Liquid Meal
Description: Subjects will receive liquid meals, during meal study
Study NCT02929212 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: All subjects given acetaminophen to measure gastric emptying
Study NCT02929212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Single, 600 kcal meal
Description: Subjects will receive a single, 600 kcal meal during meal study
Study NCT02929212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multiple, 200 kcal meals
Description: Subjects will receive three, 200 kcal meals, during meal study
Study NCT02773654 — intervention group
Intervention type: OTHER
Intervention: Healthy Volunteers
Description: Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
Study NCT04076995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Intake
Description: Increased water intake during the 11 h protocol
Study NCT02110407 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: training
Description: intensive training of visual-spatial abilities (in LOCATO task)
Study NCT02110407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Description: intensive training of visual-spatial abilities (in LOCATO task)
Study NCT01009645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fact Only Education Message
Description: Participants randomized to this intervention will receive an educational brochure listing the facts of the influenza vaccine.
Study NCT02773654 — intervention group
Intervention type: OTHER
Intervention: Symptomatic Volunteers
Description: Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
Study NCT01647334 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive radiotherapy
Study NCT03652467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TACE
Description: Conventional chemoembolization drugs are injected through hepatic artery.
Study NCT03652467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine and conventional TACE
Description: Deferoxamine is injected before conventional transarterial chemoembolization.
Study NCT00902174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
Study NCT00902174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to imatinib 100 mg film coated tablets
Study NCT01833000 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler
Study NCT02095509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Drug class: Low-molecular weight heparin
Study NCT03930407 — intervention group
Intervention type: PROCEDURE
Intervention: The Hayman uterine compression suture.
Description: Hayman suture is a common technique for uterine compression to stop bleeding due to uterine atony. Hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterectomy. It is usually employed to overcome uterine atony during cesarean section.
Study NCT02288988 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Antireflux Surgery
Description: Collis gasytroplasty Nissen antireflux fundoplication
Study NCT03339973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allo-APZ2-PAOD
Description: Suspension of ABCB5-positive mesenchymal stem cells in pre-filled syringe
Study NCT03339973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection in pre-filled syringe
Study NCT03106467 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic appendectomy
Description: Single-port laparoscopic appendectomy: A 1.5 cm skin incision is made inside the umbilicus and single port is introduced through it. The appendix is manipulated by a combination of a 5-mm scope, angulated, and straight instruments. The periappendiceal vessels and appendix are ligated and divided. Specimen is delivered via the transumbilical port. Umbilical fascia and skin are routinely closed.
Study NCT03106467 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three-port laparoscopic appendectomy
Description: Three-port laparoscopic appendectomy: CLA requires the introduction of a 30-degree 5-mm or 10-mm rigid scope through a 0.5 - 1.0 cm intra umbilical incision. Two additional 5-mm incisions are made outside umbilicus. Appendectomy is performed in the same manner as described for the SLA above. The umbilical fascia and skin are routinely closed.
Study NCT03536026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional bronchoscopy
Description: -Standard of care
Study NCT03536026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIDA Pulmonary Workstation 2
Description: -Virtual bronchoscopic navigation system
Study NCT03536026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: -Standard of care
Study NCT01518504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Mobilization
Description: The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
Study NCT01518504 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
Study NCT03403309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1) Inosine 5'-monophosphate
Description: 1) Subjects are initiated with 1 tablet (500mg of inosine 5'-monophosphate per one tablet) two times per day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL, so that reducing dose of administration may be considered in case of being way over the top of limited level.
Study NCT03403309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2) Subjects are initiated with 1 tablet (500mg of placebo tablet with inactive therapeutic effect) two times a day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL.
Study NCT01009645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fact and Myth Educational Message
Description: Participants randomized to this intervention will receive an educational brochure listing the facts and myths of the influenza vaccine.
Study NCT01009645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fact, Myth, Why Educational Message
Description: Participants randomized to this intervention will receive an educational brochure listing the facts, myths, and refutation of the myths of the influenza vaccine.
Study NCT01009645 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Educational Message
Description: Participants randomized to this intervention will receive an educational brochure created and used by the CDC in a previous influenza season.
Study NCT01105429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 150 mg, once daily, 1 day
Study NCT01105429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Oral Solution, Oral, 300 mg, once daily, 1 day
Study NCT02251210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS low dose
Study NCT02251210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS medium dose
Study NCT02251210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS high dose
Study NCT02251210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06135610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Postive SAR-CoV-2 PCR nasopharyngeal swab
Description: Diagnosed Covid-19 confirmed by a positive of SAR-CoV-2 PCR nasopharyngeal swab.
Study NCT00517569 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GX-12
Description: a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)
Study NCT00517569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
Study NCT00480870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
Study NCT00480870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1p / day for 1 month and 2 / day for 5 months on
Study NCT02266212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5 ml arterial blood
Description: A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
Study NCT06380010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet group
Description: Females who met the inclusion and exclusion criteria were allocated in groups of one to either the Control group or the Intervention (MD) group using a random assignment method applied by an independent statistician. During the trial, every participant in both groups had two individual sessions with the assigned researchers. These sessions took place at the beginning of the trial and three months later, and involved anthropometry measurements, evaluation of dietary habits, assessment of psychological well-being, and collection of blood samples. Treatment allocation was not revealed to the appointed statistician until the end of the study and release of the final outcomes.
Study NCT02303106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Study NCT02303106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Study NCT05296031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with Zilver PTX Drug Eluting Stent (DES) in femoropopliteal lesions
Description: Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
Study NCT05296031 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treatment with Zilver Flex Bare Metal Stent (BMS) in femoropopliteal lesions
Description: Randomized trial comparing drug eluting stent Zilver PTX vs Bare metal stent Zilver Flex in critical limb ischemia and treatment of lesions in femoral and popliteal arteries
Study NCT03762447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB086550
Description: INCB086550 will be orally administered once or twice daily in continuous or intermittent dose schedules.
Study NCT02090361 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: skin graft
Description: Epidermization of the defect by applying a thin layer of autologous epidermis
Study NCT01105429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, (TBD), once daily, 2 days
Study NCT01105429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0mg, once daily, 1 day
Study NCT02090361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin graft
Description: Epidermization of the defect by applying a thin layer of autologous epidermis
Study NCT02705274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.~Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met.
Study NCT02705274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation
Description: Panretinal photocoagulation (full session completed within 42 days).
Study NCT02705274 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal photocoagulation
Description: Panretinal photocoagulation (full session completed within 42 days).
Study NCT01371045 — intervention group
Intervention type: OTHER
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
Study NCT02024126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: Exercise therapy
Study NCT02024126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Exercise therapy
Study NCT03139617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Iliaca Compartment Block (FICB)
Description: The FICB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block. Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel. Lignocaine 2% for local anaesthetic infiltration at punctured site.A blunted needle (Plexufix® 24G x 2, B Braun Melsungen AG 34209 Germany).A line was drawn from pubic tubercle to anterior superior iliac spine, the punctured point is 2-3cm distal to the point where medial 2/3rd and lateral 1/3rd of the line meet. Loss of resistance 2 times indicated the punctured of fascia lata and iliaca.A total volume of Ropivacaine 0.375% per body weight was given with repeated aspiration.
Study NCT03139617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 in 1 femoral block (FNB)
Description: The FNB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block.Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel.Lignocaine 2% for local anaesthetic infiltration at punctured site.An insulated stimulating needle (Stimuplex® D Plus 22g x 2, B Braun Melsungen AG 34209 Melsungen Germany). Ultrasound was used to locate the femoral vessel and nerve and by using 'in plane' technique, the skin was punctured with the insulated needle and advance in transverse plane at around 30 angle to the skin. Local anaesthetic solution as per ideal body weight given after negative aspiration of blood .
Study NCT04076995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water Intake
Description: Increased water intake during the 11 h protocol
Study NCT03775564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REMEDRUGBY PROGRAM
Description: * 1st Session presentation of the programme, its objectives and a common reflection on the concepts of stigmatization/destigmatization.~* 2nd to 4th session devoted to a group reflection on social conventions and their meaning followed by a practice by means of role-playing.~* 5th to 7th session devoted to writing comments about tournaments on the blog by working on the intentions of others and the emotional impact of comments on their recipients.~* 8th, 9th 11th sessions devoted to media relations with group reflection on the image of themselves and their pathology that participants wish to refer to the media, followed by a practice in role-playing games Interviewer-interviewed~* 10th session devoted to planning and organizing the day of matches with writing a program of the day and spreading on the blog~* 12th General Debriefing session Including : - 3 tournaments~* 8 hours of Touch Rugby
Study NCT03775564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TOUCH RUGBY PROGRAM
Description: Practical training Program at Touchrugby at the rate of 12 weekly sessions of 2 hours and 3 inter-institutional tournaments per day
Study NCT03775564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAU
Description: Treatment as usual